BillionToOne Northstar Select, Northstar Response

BillionToOne has launched its first oncology liquid biopsy products, Northstar Select and Northstar Response. The assays are currently available for research use with select academic cancer centers, but the firm intends a full commercial launch early next year.

Northstar Select is a comprehensive pan-cancer somatic mutation profiling panel and Northstar Response is a methylation-based, tissue-agnostic treatment response monitoring assay. Both employ BillionToOne’s proprietary molecular counting technology, called Quantitative Counting Templates, which the firm said enables a low limit of detection for identification of actionable alterations.